Newly Developed Migraine Pill with Lifechanging Effects to Hit the Market Within Months, Reducing Attacks by Half

by
Newly Developed Migraine Pill with Lifechanging Effects to Hit the Market Within Months, Reducing Attacks by Half
  • Taken daily, trials have shown that this drug has twice the success rate of current tablets in reducing migraine attacks.

By Kate Pickles, Health Editor


Updated:






















Millions of people who suffer from migraines are on the verge of receiving a new medication that could cut their attacks in half.

Results from trials of atogepant, taken as a daily pill, have shown a significant reduction in migraines from an average of eight per month to just four – twice the success rate of the current tablets available.

The Medicines and Healthcare products Regulatory Agency has already licensed the drug, and pending approval from the National Institute for Health and Care Excellence, it is expected to be available to patients in the coming months.

Newly Developed Migraine Pill with Lifechanging Effects to Hit the Market Within Months, Reducing Attacks by Half

Millions of migraine sufferers could soon benefit from a new drug which has been found to reduce attacks by half

Taken as a daily pill, trials of atogepant revealed it cut migraines from an average of eight to four a month – double the success of current tablets

Taken as a daily pill, trials of atogepant revealed it cut migraines from an average of eight to four a month – double the success of current tablets

This new drug, called atogepant, functions as a CGRP inhibitor and works by blocking the activity of calcitonin gene-related peptide, a protein known to trigger migraines.

Developed by AbbVie, a company based in the US, the estimated annual cost of this medication is approximately £8,000.

Professor Peter Goadsby, who led the discovery of CGRP in the 1980s at King’s College Hospital, believes that this drug could be life-changing for migraine sufferers.